Phase II study of high-dose epirubicin in non-small cell lung cancer

Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC Study

“…The administration of high-dose bolus epirubicin does not appear to increase the incidence of cardiotoxicity, even at cumulative doses above 750 mg/m2 [ 18], Epirubi cin, used at increased dose levels between 120 and 165 mg/m2, showed activity in NSCLC [3,19,20], The 25% response rates obtained and median survival about 30 weeks are comparable to the results obtained with a vari ety of cisplatin-containing regimens. For NSCLC, several studies with epirubicin-containing combinations have been published in the last years.…”

Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC Study

“…The administration of high-dose bolus epirubicin does not appear to increase the incidence of cardiotoxicity, even at cumulative doses above 750 mg/m2 [ 18], Epirubi cin, used at increased dose levels between 120 and 165 mg/m2, showed activity in NSCLC [3,19,20], The 25% response rates obtained and median survival about 30 weeks are comparable to the results obtained with a vari ety of cisplatin-containing regimens. For NSCLC, several studies with epirubicin-containing combinations have been published in the last years.…”

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

“…In a study by Martoni et al, it was discovered that a higher dose of epirubicin was linked to a higher decrease in LVEF values, but no systematic pattern was observed in decrease of LVEF values across cohorts of different dosage and accumulated dosage, so it cannot be concluded that whether certain single and/or accumulated dosage of epirubicin possibly caused a decrease in LVEF values (Martoni et al, 1991). But this assumption can be supported by other studies, which concluded that epirubicin was associated with cumulative-dose cardiotoxicity (Wils et al, 1990;Feld et al, 1992;Smit et al, 1992). Others, such as daunorubicin, are believed to cause indirect damage to the heart by interfering with calcium homeostasis.…”

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study

“…Disadvantages of the administration of cisplatin are its toxicity and the use of hydration schedules, which will often necessitate hospitalization. High-dose single-agent epirubicin is effective in NSCLC (Wils et al, 1990;Smit et al, 1992). In our institution, prior research was performed on the efficacy of high-dose epirubicin in advanced NSCLC (Smit et al, 1992;Bakker et al, 1995).…”

Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC Study

“…The administration of high-dose bolus epirubicin does not appear to increase the incidence of cardiotoxicity, even at cumulative doses above 750 mg/m2 [ 18], Epirubi cin, used at increased dose levels between 120 and 165 mg/m2, showed activity in NSCLC [3,19,20], The 25% response rates obtained and median survival about 30 weeks are comparable to the results obtained with a vari ety of cisplatin-containing regimens. For NSCLC, several studies with epirubicin-containing combinations have been published in the last years.…”

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

“…In a study by Martoni et al, it was discovered that a higher dose of epirubicin was linked to a higher decrease in LVEF values, but no systematic pattern was observed in decrease of LVEF values across cohorts of different dosage and accumulated dosage, so it cannot be concluded that whether certain single and/or accumulated dosage of epirubicin possibly caused a decrease in LVEF values (Martoni et al, 1991). But this assumption can be supported by other studies, which concluded that epirubicin was associated with cumulative-dose cardiotoxicity (Wils et al, 1990;Feld et al, 1992;Smit et al, 1992). Others, such as daunorubicin, are believed to cause indirect damage to the heart by interfering with calcium homeostasis.…”

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study

“…Disadvantages of the administration of cisplatin are its toxicity and the use of hydration schedules, which will often necessitate hospitalization. High-dose single-agent epirubicin is effective in NSCLC (Wils et al, 1990;Smit et al, 1992). In our institution, prior research was performed on the efficacy of high-dose epirubicin in advanced NSCLC (Smit et al, 1992;Bakker et al, 1995).…”

Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC Study

“…The administration of high-dose bolus epirubicin does not appear to increase the incidence of cardiotoxicity, even at cumulative doses above 750 mg/m2 [ 18], Epirubi cin, used at increased dose levels between 120 and 165 mg/m2, showed activity in NSCLC [3,19,20], The 25% response rates obtained and median survival about 30 weeks are comparable to the results obtained with a vari ety of cisplatin-containing regimens. For NSCLC, several studies with epirubicin-containing combinations have been published in the last years.…”

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

“…In a study by Martoni et al, it was discovered that a higher dose of epirubicin was linked to a higher decrease in LVEF values, but no systematic pattern was observed in decrease of LVEF values across cohorts of different dosage and accumulated dosage, so it cannot be concluded that whether certain single and/or accumulated dosage of epirubicin possibly caused a decrease in LVEF values (Martoni et al, 1991). But this assumption can be supported by other studies, which concluded that epirubicin was associated with cumulative-dose cardiotoxicity (Wils et al, 1990;Feld et al, 1992;Smit et al, 1992). Others, such as daunorubicin, are believed to cause indirect damage to the heart by interfering with calcium homeostasis.…”

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study

“…Disadvantages of the administration of cisplatin are its toxicity and the use of hydration schedules, which will often necessitate hospitalization. High-dose single-agent epirubicin is effective in NSCLC (Wils et al, 1990;Smit et al, 1992). In our institution, prior research was performed on the efficacy of high-dose epirubicin in advanced NSCLC (Smit et al, 1992;Bakker et al, 1995).…”